Andrzej Mogielnicki

Prof. Andrzej Mogielnicki

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2007 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
SCStefan Chlopicki
Stefan Chlopicki
JSJ Swies
J Swies
Andrzej MogielnickiAndrzej Mogielnicki
Andrzej Mogielnicki
WBW Buczko
W Buczko
MBM Bartus
M Bartus
JGJerzy Gebicki
Jerzy Gebicki

6 June 2016 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Closed access
ESEmilia Sokołowska
Emilia Sokołowska
BKBartlomiej Kalaska
Bartlomiej Kalaska
JMJoanna Miklosz
Joanna Miklosz
Andrzej MogielnickiAndrzej Mogielnicki
Andrzej Mogielnicki
Introduction: Unfractionated heparin is a strongly anionic anticoagulant used extensively in medicine to prevent blood clotting. In the case of an emergency bleeding in response to heparin, the protamine sulfate is administered. Despite its extensive clinical use, protamine may produce life-threatening side effects such as systemic hypotension, catastrophic pulmonary vasoconstriction or allergic reactions. Recent studies have demonstrated new organ-specific complications of the heparin reversal with protamine. Areas covered: Past and present knowledge of the mechanisms responsible for the toxicity of protamine and the most promising potential replacements of protamine in the different phases of development. Expert opinion: Despite of the low therapeutic index, protamine is the only registered antidote of heparins. The toxicology of protamine depends on a complex interaction of the high molecular weight, a cationic peptide with the surfaces of the vasculature and blood cells. The mechanisms involve membrane receptors and ion channels targeted by different vasoactive compounds, such as nitric oxide, bradykinin or histamine. Unacceptable side effects of protamine have led to a search for new alternatives: UHRA, LMWP, and Dex40-GTMAC3 are in the preclinical stage; the two other agents (andexanet alfa and PER977) are already in the advanced clinical phases.

1 September 2012 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Open access
PDF file
KKKarol Kramkowski
Karol Kramkowski
ALAgnieszka Leszczynska
Agnieszka Leszczynska
Andrzej MogielnickiAndrzej Mogielnicki
Andrzej Mogielnicki
SCStefan Chlopicki
Stefan Chlopicki
AFAndrzej Fedorowicz
Andrzej Fedorowicz
WBWlodzimierz Buczko
Wlodzimierz Buczko
Objective—We compared the antithrombotic effects in vivo of 2 chemically different carbon monoxide–releasing molecules (CORM-A1 and CORM-3) on arterial and venous thrombus formation and on hemostatic parameters such as platelet activation, coagulation, and fibrinolysis. The hypotensive response to CORMs and their effects on whole blood gas analysis and blood cell count were also examined. Methods and Results—CORM-A1 (10–30 µmol/kg, i.v.), in a dose-dependent fashion, significantly decreased weight of electrically induced thrombus in rats, whereas CORM-3 inhibited thrombosis only at the highest dose used (30 µmol/kg). CORM-A1 showed a direct and stronger inhibition of platelet aggregation than CORM-3 in healthy rats, both in vitro and in vivo. The antiaggregatory effect of CORM-A1, but not CORM-3, correlated positively with weight of the thrombus. Concentration of active plasminogen activator inhibitor-1 in plasma also decreased in response to CORM-A1, but not to CORM-3. Neither CORM-A1 nor CORM-3 had an effect on plasma concentration of active tissue plasminogen activator. CORM-3, but not CORM-A1, decreased the concentration of fibrinogen, fibrin generation, and prolonged prothrombin time. Similarly, laser-induced venous thrombosis observed intravitally via confocal system in green fluorescent protein mice was significantly decreased by CORMs. Although both CORM-A1 and CORM-3 (30 µmol/kg) decreased platelets accumulation in thrombus, only CORM-A1 (3–30 µmol/kg) inhibited platelet activation to phosphatidylserine on their surface. Conclusion—CORM-3 and CORM-A1 inhibited thrombosis in vivo, however CORM-A1, which slowly releases carbon monoxide, and displayed a relatively weak hypotensive effect had a more pronounced antithrombotic effect associated with a stronger inhibition of platelet aggregation associated with a decrease in active plasminogen activator inhibitor-1 concentration. In contrast, the fast CO releaser CORM-3 that displayed a more pronounced hypotensive effect inhibited thrombosis primarily through a decrease in fibrin generation, but had no direct influence on platelet aggregation and fibrynolysis.

25 February 2012 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Open access
PDF file
SCStefan Chlopicki
Stefan Chlopicki
MLMagdalena Lomnicka
Magdalena Lomnicka
AFAndrzej Fedorowicz
Andrzej Fedorowicz
EGElżbieta Grochal
Elżbieta Grochal
KKKarol Kramkowski
Karol Kramkowski
Roberto MotterliniRoberto Motterlini
Roberto Motterlini
Carbon monoxide (CO) and CO-releasing molecules (CO-RMs) inhibit platelet aggregation in vitro. Herein, we compare the anti-platelet action of CORM-3, which releases CO rapidly (t ½ 1 min), and CORM-A1, which slowly releases CO (t½ = 21 min). The anti-platelet effects of NO donors with various kinetics of NO release were studied for comparison. The effects of CO-RMs and NO donors were analyzed in washed human platelets (WP), platelets rich plasma (PRP), or whole blood (WB) using aggregometry technique. CORM-3 and CORM-A1 inhibited platelet aggregation in human PRP, WP, or WB, in a concentration-dependent manner. In all three preparations, CORM-A1 was more potent than CORM-3. Inhibition of platelets aggregation by CORM-A1 was not significantly affected by a guanylate cyclase inhibitor (ODQ) and a phosphodiesterase-5 inhibitor, sildenafil. In contrast, inhibition of platelet aggregation by NO donors was more potent with a fast NO releaser (DEA-NO, t ½ = 2 min) than slow NO releasers such as PAPA-NO (t ½ = 15 min) or other slow NO donors. Predictably, the anti-platelet effect of DEA-NO and other NO donors was reversed by ODQ while potentiated by sildenafil. In contrast to NO donors which inhibit platelets proportionally to the kinetics of NO released via activation of soluble guanylate cyclase (sGC), the slow CO-releaser CORM-A1 is a superior anti-platelet agent as compared to CORM-3 which releases CO instantly. The anti-platelet action of CO-RMs does not involve sGC activation. Importantly, CORM-A1 or its derivatives representing the class of slow CO releasers display promising pharmacological profile as anti-platelet agents.

1 January 2005 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
Andrzej MogielnickiAndrzej Mogielnicki
Andrzej Mogielnicki
ECEwa Chabielska
Ewa Chabielska
RPRobert Pawlak
Robert Pawlak
JSJanusz Szemraj
Janusz Szemraj
WBWlodzimierz Buczko
Wlodzimierz Buczko
Summary: There is an increased number of in vitro evidence that angioten-sin II (Ang II) may promote thrombosis. However there are no in vivo experiments exploring the effect of Ang II on thrombus formation. In the present study we have investigated the influence of Ang II on venous thrombosis in renovascular hypertensive rats. Furthermore, we examined the role of AT1 receptor and Ang II metabolites: angiotensin III (Ang III) and angioten-sin IV (Ang IV) in the mechanisms of Ang II action. The contribution of coagulation and fibrinolytic systems in the mode of Ang II action was also determined. Venous thrombosis was induced by ligation of vena cava. Ang II infused into rats developing venous thrombosis caused dose-dependent increase in thrombus weight, which was partially reversed by losartan, selective AT1 antagonist. Ang III did not influence the thrombus formation in hypertensive rats, while Ang IV caused a marked increase in thrombus weight only in one of the used doses. Our study shows that Ang II via AT1 receptor enhances thrombosis development. The prothrombotic effect of Ang II may partially depend on enhanced leukocytes adhesion to endothelial cells accompanied by accelerated fibrin formation and increased plasma level of PAI-1. Moreover, Ang II action is partially mediated by one of its metabolites – Ang IV.

13 March 2014 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
BKBartlomiej Kalaska
Bartlomiej Kalaska
LPLukasz Piotrowski
Lukasz Piotrowski
ALAgnieszka Leszczynska
Agnieszka Leszczynska
Bartosz MichalowskiBartosz Michalowski
Bartosz Michalowski
KKKarol Kramkowski
Karol Kramkowski
WBWlodzimierz Buczko
Wlodzimierz Buczko